Alunbrig (Brigatinib) Patent Expiration, LOE Window & CMS Spending

Alunbrig (Brigatinib) by Takeda: FDA Orange Book core substance LOE 2035-11-10, 0 AB generics, $52.0M 2024 CMS Part D & Medicaid spend, and 20 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTakeda
FDA Application & PathwayN208772 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2035-11-10
Last Listed Patent or Exclusivity Date2035-11-10
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$52.0M
2024 Medicare Part D Spend$41.9M
2024 Medicaid Spend$10.1M
Reported Wholesale Price Change (CA SB 17)20 WAC filings (max 18.7% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.